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Abstract
TNF-α has a central role in the development and maintenance of psoriatic plaques, and its
serum levels correlate with disease activity. Anti-TNF-α drugs are, however, ineffective in a
relevant percentage of patients for reasons that are currently unknown. To understand
whether the response to anti-TNF-α drugs is influenced by the production of anti-drug anti-
bodies or by the modulation of the TNFα-TNFα receptor system, and to identify changes in
monocyte phenotype and activity, we analysed 119 psoriatic patients who either responded
or did not respond to different anti-TNF-α therapies (adalimumab, etanercept or infliximab),
and measured plasma levels of TNF-α, TNF-α soluble receptors, drug and anti-drug anti-
bodies. Moreover, we analyzed the production of TNF-α and TNF-α soluble receptors by
peripheral blood mononuclear cells (PBMCs), and characterized different monocyte popula-
tions. We found that: i) the drug levels varied between responders and non-responders; ii)
anti-infliximab antibodies were present in 15% of infliximab-treated patients, while anti-eta-
nercept or anti-adalimumab antibodies were never detected; iii) plasma TNF-α levels were
higher in patients treated with etanercept compared to patients treated with adalimumab or
infliximab; iv) PBMCs from patients responding to adalimumab and etanercept produced
more TNF-α and sTNFRII in vitro than patients responding to infliximab; v) PBMCs from
patients not responding to infliximab produce higher levels of TNF-α and sTNFRII than
patients responding to infliximab; vi) anti- TNF-α drugs significantly altered monocyte sub-
sets. A complex remodelling of the TNFα-TNFα receptor system thus takes place in patients
treated with anti-TNF-α drugs, that involves either the production of anti-drug antibodies or
the modulation of monocyte phenotype or inflammatory activity.
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Introduction
Psoriasis, also defined as plaque psoriasis or psoriasis vulgaris, is a chronic inflammatory dis-
ease characterized by the infiltration of inflammatory cells in the skin and hyper-proliferation
of keratinocytes, resulting in red-coloured plaques, mainly located on elbows, knees, scalp and
in the sacral area [1–3]. Although the molecular mechanisms driving the pathogenesis of psori-
asis is still unknown, both immune system dysregulation and environmental factors, including
diet, psychosocial stress, certain drugs and infections, are critically involved [4–7]. The main
immune cells involved in psoriasis are myeloid dendritic cells (mDCs) and T lymphocytes.
Myeloid DCs sustain the activation and differentiation of several T cell subsets, including type-
1 helper T cells (Th1), type-17 helper T cells (Th17), and γδ T cells. These cells secrete a num-
ber of specific cytokines, including tumour necrosis factor (TNF)-α, interferon (IFN)-γ, inter-
leukin (IL)-1, IL-6, IL-17A, IL-17F and IL-22, which play a role in the pathogenesis of psoriasis
[3, 8].
Among these cytokines, TNF-α is a crucial pathogenetic driver. TNF-α binds two different
cell-membrane receptors, TNF receptor (TNFR) type 1, also known as p55, and TNFR2, also
known as p75. Soluble forms of these receptors, namely soluble TNFR1 (sTNFR1) and soluble
TNFR2 (sTNFR2), have also been identified and likely act as endogenous TNF-α inhibitors.
Increased levels of sTNFR1 have been found in serum from patients with psoriasis [9]. TNF-α
modulates the activity of various cells. Firstly, it induces the maturation of DCs, and skews
monocyte differentiation from macrophages to DCs, thus favouring adaptive immunity [10].
Secondly, it promotes the expression of adhesion molecules, including intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, on dermal
vascular endothelial cells. Thirdly, it induces the expression of chemokines, such as chemokine
ligand (CCL)-20, CCL5, and CCL2 on keratinocytes and dermal fibroblasts [11].
Several TNF-α blockers, including neutralizing antibodies and soluble TNF-α receptors,
have been developed, and are currently used in clinical practice. Adalimumab, etanercept and
infliximab represent the first-generation inhibitors targeting TNF-α, and are largely used in
clinical settings. Adalimumab is a fully human monoclonal antibody, while infliximab is a chi-
meric human/mouse monoclonal antibody containing almost 75% human-derived amino
acids and almost 25% mouse-derived amino acids. Etanercept is a fusion protein where a
dimer of the extracellular domains of human TNFR2 is fused to the Fc portion of human IgG1
[12].
Anti-TNF-α drugs provide remission in a great proportion of patients, reducing inflamma-
tion and decreasing the “Psoriasis Area and Severity Index” (PASI) [13–15]. However, a rele-
vant percentage of patients fails to respond to treatment [16, 17]. The mechanisms driving the
different clinical responses to anti-TNF-α drugs are still unknown, but are a crucial issue con-
sidering the high cost of these drugs and the risk of rare but severe adverse events. Several
mechanisms have been proposed to explain the different responses, including i) the presence
of genetic polymorphisms in genes encoding proteins of the TNF-α system [18, 19], and ii) the
formation of neutralising and non-neutralising anti-drug antibodies (ADAs) [20]. We aimed
to investigate whether anti-TNF-α drugs impair the functional capacity of PBMCs to respond
to lipopolysaccharide (LPS) and/or induce modifications among the main populations of
monocytes, which are the major producers of TNF-α. To address this question, we quantified
plasma levels of ADAs, TNF-α, sTNFRI and sTNFRII, examined the functional capacity of
PBMCs to respond to lipopolysaccharide (LPS), and characterized the main populations of
monocytes in a large cohort of patients with psoriasis treated with different biological drugs
(anti-TNF), including responders and non-responders to treatment.
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Methods
Study design and clinical cohort
A total of 119 patients with psoriasis and psoriatic arthritis were enrolled at the Department of
Dermatology of the University of Modena and Reggio Emilia (Modena, Italy). Of these, 48
were treated with adalimumab (standard dosage for psoriasis), 30 with etanercept (standard
dosage for psoriasis), 41 with infliximab (standard dosage for psoriasis). Twenty healthy con-
trols (HC, median age 50.1, range 26–69) were also enrolled. Patients’ demographic and clinical
characteristics are shown in Table 1. In each group, on the basis of the PASI, patients were
divided into two subgroups: responders (R) and non-responders (NR). R were defined as hav-
ing a 75% reduction in PASI compared to baseline (PASI 75) within six months of treatment.
NR were those who did not achieve a 50% reduction in PASI compared to baseline within six
months of treatment. Patients achieving a response comprised between 50% and 75% in PASI
were included in the NR group. Ninety-five percent of patients enrolled in this study had been
suffering from psoriasis for more than five years. Moreover, according to national and interna-
tional guidelines for the treatment of psoriasis, therapies based on biologics are restricted to
patients with moderate to severe psoriasis. Therefore, before the beginning of treatment, the
mean baseline PASI was 16.42 (SD: 3.73). Given the long and relapsing nature of the disease,
35.3% of patients were receiving their first biological drug, whereas 64.7% had been previously
treated with other biologics and then switched to the current treatment for at least 6 months.
Patients could be included if they were 18 years of age or older, if they did not present any rele-
vant autoimmune comorbidities, if they had not received prior treatment with anti-TNF drugs
or if the last drug treatment lasted at least six months, and if they had suspended treatment in
the last four months before sampling. Enrolment of patients started on August 26th 2014 and
ended on April 20th 2015. Blood samples were collected during the follow-up visits of patients
receiving biological drugs. For patients treated with etanercept or adalimumab, blood samples
were obtained three months after the last drug injection, while for patients treated with inflixi-
mab, blood samples were obtained two months after the last drug infusion. The study was
approved by the local Ethical Committee of Modena (identification code number 296/13) and
by the Institutional Review Board of the Dept. of Surgery, Medicine, Dentistry and Morpholog-
ical Sciences of the University of Modena and Reggio Emilia, and was conducted according to
the Declaration of Helsinki principles. Signed consent forms were collected from all patients.
Twenty ml of venous blood were collected from each patient into ethylenediamine-tetraace-
tic acid (EDTA) tubes. Samples were centrifuged and plasma was stored at -80˚C. Peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density gradient according
to standard procedures and stored in liquid nitrogen until use.
Quantification of plasma levels of TNF-α, sTNFRI, sTNFRII
The plasma levels of TNF-α, sTNFRI, sTNFRII were quantified by Quantikine ELISA kit
(R&D Systems, Minneapolis, MN, USA), following instructions provided by the manufacturer.
Table 1. Demographic and clinical characteristics of patients.
Adalimumab (n = 48) Etanercept (n = 30) Infliximab (n = 41)
Median age, years (range) 54 (26–81) 54 (24–82) 53 (29–80)
Gender, % male 62.5 86.7 82.9
Therapy effectiveness, % responders 62.5 66.7 80.8
Psoriatic arthritis, % presence 83.3 56.6 56.0
Received previous biologic therapy, % 62.5 40.0 85.3
doi:10.1371/journal.pone.0167757.t001
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In particular, the following kits were used: human TNF-α Quantikine HS ELISA kit (catalog
number HSDTA00D), human sTNFRI/TNFRSF1A Quantikine ELISA Kit (catalog number
DRT100), and human sTNFRII/TNFRSF1B Quantikine ELISA Kit (catalog number DRT200).
Quantification of plasma levels of etanercept, anti-etanercept antibodies,
adalimumab, anti-adalimumab antibodies, infliximab and anti-infliximab
antibodies
The plasma levels of etanercept, anti-etanercept antibodies, adalimumab, anti-adalimumab
antibodies, infliximab and anti-infliximab antibodies were quantified by the following ELISA
kits: shikari Q-ETA, shikari S-ATE, shikari Q-ADA, shikari S-ATA, shikari Q-INFLIXI and
shikari Q-ATI (all from Matriks Biotechnology, Ankara, Turkey).
Stimulation of PBMCs with lipopolysaccharide (LPS)
PBMCs were thawed and plated in RPMI-1640 complete medium (10% foetal bovine serum,
1% penicillin/streptomycin, 2 mM L-glutamine; all from Life Technologies Corporation, Carls-
bad, CA, USA) with or without 50 ng/mL LPS (Sigma Aldrich, St. Louis, MO, USA) for 16
hours. Supernatant was collected and used for the quantification of TNF-α, sTNFRI and
sTNFRII by human TNF-α Quantikine ELISA kit (catalog number DTA00C), human sTNFRI/
TNFRSF1A Quantikine ELISA Kit and human sTNFRII/TNFRSF1B Quantikine ELISA Kit.
Flow cytometric analysis of monocytes
PBMCs were thawed according to standard procedures [21]. Monocytes were identified on the
basis of their size, granularity and expression of HLA-DR and CD14, by using polychromatic
flow cytometry. Living cells were identified for the negativity to Red fixable live dead (Thermo-
fisher, Eugene, OR, USA). Then, three populations of monocytes were identified on the basis
of anti-CD14 APC (Becton Dickinson, San Jose´, CA, USA) and -CD16 FITC (BD) expression.
The expression of HLA-DR (PE-conjugated, BD) was evaluated among different monocyte
subpopulation. Anti-CD3-V450, anti-CD19-V450 and anti-CD56-V450 were used for the
DUMP channel. Samples were washed twice and immediately analysed by using an Attune
Nxt Acoustic Focusing Cytometer (Thermofisher). The instrument is equipped with a blue
laser (488 nm), a red laser (637 nm), a yellow laser (561 nm), and a violet laser (405 nm). Data
were acquired in the list mode using Attune Cytometric 2.1 software and then analysed by
FlowJo 9.9 (Tree Star Inc, Ashland, OR, USA) under Mac OSX [22].
Statistical analysis
Kruskal-Wallis test with Dunn’s Multiple Comparison Test was used to compare TNF-α,
sTNFRI and sTNFRII plasma levels in patients from different groups. Mann-Whitney test was
used to compare drug concentration among different groups. All statistical analyses were per-
formed by using Prism 5.0 software (GraphPad, La Jolla, CA, USA); a p-value<0.05 was con-
sidered significant [23]. Principal component analysis was performed by using MatLab
software, version R2013a.
Results
Patient characteristics and clinical response
We studied 119 patients receiving biological drugs, whose plasma was screened for TNF-α,
sTNFRI and sTNFRII, drug and anti-drug antibodies levels. Among patients treated with
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adalimumab (mean age: 54 years, range: 26–81), 30 were R (62.5%) and 18 were NR (37.5%);
among patients treated with etanercept (mean age: 54, range: 24–82), 20 were R (66.7%) and
10 were NR (33.3%); among patients treated with infliximab (mean age: 53, range: 29–80), 29
were R (70.8%) and 12 were NR (29.2%).
Plasma levels of drugs and anti-drug antibodies
As shown in Fig 1A, the mean plasma concentration of adalimumab in R was 4.39 μg mL-1
(range: 0.002–9.89), and a significant difference was observed between R and NR (4.39±0.6 vs.
2.47±0.76 μg mL-1, p<0.05). Concerning etanercept, the mean concentration of the drug was
higher in NR (3.91±0.01 μg mL-1) than in R (3.27±0.23 μg mL-1, p<0.05, Fig 1B). In patients
treated with infliximab, the mean concentration of the drug was 2.63 μg mL-1 (range: 0.04–
9.29 μg mL-1) in R, and 1.63 μg mL-1 in NR (range: 0.04–7.14 μg mL-1), and no significant dif-
ferences were observed between R and NR (Fig 1C).
Studies in the literature have shown that ADA for adalimumab are often present in patients
assuming this drug. In our study, while anti-drug antibodies were undetectable in patients
treated with adalimumab and etanercept, anti-drug antibodies were detected in the plasma of
6 out of 38 (15.8%) patients treated with infliximab (Fig 1D). No significant difference was
found among R and NR, and in most patients (5 out of 6) plasma levels of infliximab were
<0.5 μg mL-1 (Fig 1E).
Plasma levels of TNF-α, sTNFRI and sTNFRII
Plasma levels of TNF-α, sTNFRI and sTNFRII were quantified by ELISA. Results concerning
plasma levels of TNF-α, sTNFRI and sTNFRII are reported in Fig 2A–2C. To have reference
value, TNF-α, sTNFRI and sTNFRII levels were also quantified in 20 HC. TNF-α sTNFRI, and
sTNFRII levels in HC were 0.83±0.14 pg mL-1, 942.2±31.77 ng mL-1 and 2,587±75.85 ng mL-1.
TNF-α concentration in plasma from patients treated with etanercept was significantly higher
compared to those treated with adalimumab or infliximab. Patients responding to etanercept
had higher levels of TNF-α compared to patients responding to adalimumab or infliximab. No
differences were detected between R and NR to the different treatments. Levels of sTNFRI or
sTNFRII were similar among all groups of patients (Fig 2B and 2C). As shown in Fig 2D, no
correlation between plasma levels of TNF-α and plasma levels of sTNFRI was observed. Con-
versely, a correlation was present between plasma levels of TNF-α and plasma levels of
sTNFRI, as well as between plasma of sTNFRI and sTNFRII (Fig 2E and 2F). We also found
that, among all patients, plasma levels of sTNFRI and sTNFRII, but not TNF-α, correlate with
age (Fig 2G–2I). Explorative principal component analysis on immunologic parameters
revealed that R and NR to the different treatments did not form distinct clusters (Fig 3).
In vitro activity of PBMCs from patients
In order to evaluate whether anti-TNF-α drugs affected the spontaneous production of cyto-
kines in PMBCs together with their capacity to respond to LPS, cells were cultured in the pres-
ence of LPS for 16 hours, and supernatants were assayed for the production of TNF-α, sTNFRI
and sTNFRII. Results are reported in Fig 4A–4C. Interestingly, PBMCs from patients not
responding to infliximab produce higher levels of TNF-α than PBMCs obtained from patients
responding to treatment with infliximab. Moreover, PBMCs obtained from patients respond-
ing to adalimumab or etanercept produced higher levels of TNF-α than PBMCs from inflixi-
mab-treated patients, at the basal levels or in the presence of LPS.
Concerning sTNFRI, PBMCs obtained from patients responding to adalimumab produced
higher levels of sTNFRI than PBMCs from patients responding to infliximab. PBMCs obtained
Anti-TNFαDrugs and TNFα-sTNFR System in Patients with Psoriasis
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from patients treated with etanercept and not responding to therapy produce lower levels of
sTNFRI than PBMCs from R. Concerning sTNFRII, PBMCs obtained from patients respond-
ing to adalimumab produced higher levels of sTNFRII than PBMCs from infliximab-treated
patients, at the basal levels or after LPS stimulation. PBMCs from patients responding to eta-
nercept produced higher levels of sTNFRII than PBMCs from patients treated with infliximab,
only in the presence of LPS. PBMCs from patients not responding to infliximab produce
almost two-fold levels of sTNFRII than PBMCs obtained from patients treated with infliximab
and responding to the drug.
Quantification of monocytes and expression of HLA-DR and CD14
surface markers
Monocytes represent a heterogeneous cell population that express MHC class II molecules (i.
e., HLA-DR) and can be divided into three different subsets on the basis of CD14 and CD16
Fig 1. Anti-TNF-α plasma level and anti-drug antibodies. (A) Adalimumab concentration in plasma from patients with psoriasis
who respond (R) or do not respond (NR) to therapy. *p<0.05. (B) Etanercept concentration in plasma from patients with psoriasis
who respond (responders, R) or do not respond (non responders, NR) to therapy. *p<0.05. (C) Infliximab concentration in plasma
from R or NR to therapy. (D) Anti-infliximab antibodies concentration in plasma from R (n = 3) or NR (n = 3) to therapy. (E) Number
of patients with anti-infliximab antibodies stratified according to infliximab plasma levels.
doi:10.1371/journal.pone.0167757.g001
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Fig 2. Patients treated with etanercept have higher plasma levels of TNF-α. (A) TNF-α concentrations in plasma from healthy controls (HC), and
from psoriatic patients who were R or NR to adalimumab, etanercept or infliximab. The number of patients (n) was 29 for R to adalimumab, 16 for NR to
adalimumab, 24 for R to etanercept, 12 for NR to etanercept, 30 for R to infliximab, 11 for NR to infliximab, 20 for HC. *p<0.05; **p<0.01; ***p<0.001.
(B) sTNFRI concentrations in plasma from HC, and from psoriatic patients who were R or NR to adalimumab, etanercept or infliximab. The number of
patients for each group is the same as in panel A. (C) sTNFRII concentrations in plasma from HC, and from psoriatic patients who were R or NR to
adalimumab, etanercept or infliximab. The number of patients for each group is the same as in panel A. (D) Linear regression analysis for the
correlation between plasma levels of TNF-α and plasma levels of sTNFRI. (E) Linear regression analysis for the correlation between plasma levels of
TNF-α and plasma levels of sTNFRII, (F) Linear regression analysis for the correlation between plasma levels of sTNFRI and plasma levels of
sTNFRII. (G) Linear regression analysis for the correlation between age and plasma levels of TNF-α. (H) Linear regression analysis for the correlation
between age and plasma levels of sTNFRI. (I) Linear regression analysis for the correlation between age and plasma levels of sTNFRII.
doi:10.1371/journal.pone.0167757.g002
Anti-TNFαDrugs and TNFα-sTNFR System in Patients with Psoriasis
PLOS ONE | DOI:10.1371/journal.pone.0167757 December 9, 2016 7 / 16
Fig 3. Principal component analysis bi-plot (loadings and scores). The spatial distribution of the immunological
parameters and of R and NR to different treatments is based on the first three principal components (PC). Each dot
represents a single patient. Confidential ellipses are also shown. TNFA, plasma levels of TNF-α; TNFRI, plasma levels
of sTNFRI; TNFRII, plasma levels of sTNFRII; ADA, plasma levels of adalimumab; ETA, plasma levels of etanercept;
INFLIXI, plasma levels of infliximab.
doi:10.1371/journal.pone.0167757.g003
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Fig 4. PBMCs from patients responding to adalimumab and etanercept produce higher levels of TNF-
α and sTNFRII than PBMCs from patients responding to infliximab. (A) TNF-α levels were quantified in
the supernatant of peripheral blood mononuclear cells (PBMCs) in the absence or in the presence of
lipopolysaccharide (LPS) for 24 hours. PBMCs were obtained from patients treated with adalimumab,
etanercept or infliximab. Ada, adalimumab; Eta, etanercept; Inf, infliximab; NR, non-responders; R,
Anti-TNFαDrugs and TNFα-sTNFR System in Patients with Psoriasis
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expression. Classical monocytes express CD14 and do not express CD16 (CD14++,CD16-),
non-classical monocytes express CD14 and high levels CD16 (CD14+,CD16++), and interme-
diate monocytes express high levels of CD14 and CD16 (CD14++,CD16+) [24]. Different sub-
sets of monocytes are associated with a different ability to present antigens, as well as to
different levels of proinflammatory cytokines and expression of homing receptors.
Given the importance of monocytes in inflammatory diseases, we identified these cells and
their subsets in PBMCs from patients treated with different anti-TNF-α drugs. As shown in
Fig 5, monocytes were first identified according to forward scatter (FSC) and side scatter
(SSC) (upper left panel). Then, doublets were excluded (upper right panel), and living cells
were selected for negativity to Live Dead probe (middle left panel). Cells proving positive for
CD3, CD19 and CD56 were then excluded (middle right panel), and true monocytes were
identified on the basis of the positivity for the expression of MHC-class II molecules and CD14
(lower left panel). In this population, three different monocyte subsets were identified by flow
cytometry on the basis the expression of CD14 and CD16 (lower right panel), as described
[25]. Then, to analyse the activation status of these monocyte subsets, the expression of
HLA-DR was quantified in each group. The percentage of monocyte subsets is reported in Fig
6A, 6C, 6E and 6G, and the quantification of HLA-DR in each subset is reported in Fig 6B, 6D,
6F and 6H. We found that the percentage of CD14+, as wells as the percentage of CD14++,
CD16- (i.e. classical) monocytes, was higher in patients responding to adalimumab than in
patients not responding to the same drug. A slight decrease in the percentage of classical
monocytes, although not significant, was observed in patients not responding to infliximab.
Concerning HLA-DR, its expression was slightly higher in non-classical and intermediate
monocytes from patients treated with infliximab or adalimumab compared to patients treated
with etanercept.
Discussion
The hallmark of psoriasis is an extensive inflammation affecting the skin, mainly mediated by
Th1/Th17 cytokines, with a key role of TNF-α [26, 27]. For this reason, TNF-α blockers are
used in clinical practice in patients who fail to respond to conventional therapies. A number of
clinical trials and observational studies have shown that anti-TNF-α drugs are effective in the
treatment of psoriasis, as they reduce inflammation in psoriatic lesions and reverse disease
activity. However, the effectiveness of therapies based on anti-TNF-α drugs is only partial, as a
relevant percentage of patients fail to respond to this therapy, and maintain an active disease.
Therefore, presently, it is a major challenge to understand the molecular mechanisms at the
basis of the different responses to treatments.
We found that 15.8% of patients treated with infliximab had detectable levels of ADAs,
most of them being associated with low plasma infliximab concentrations. The presence of
anti-infliximab antibodies (ATIs) has also been described in patients with Crohn’s disease
(CD) or rheumatoid arthritis (RA), with a prevalence ranging from 12% to 44% in CD, and
6–61% in RA [20, 26, 28]. According to a recent systematic review, antibodies against inflixi-
mab, etanercept and adalimumab were reported in 5.4–43.6%, 0–18.3% and 6–45% of patients
with psoriasis, respectively [29]. Regarding ATIs concentrations, we did not observe a
responders. *p<0.05; ***p<0.001. (B) sTNFRI levels were quantified in the supernatant of PBMCs in the
absence or in the presence of LPS for 24 hours. PBMCs were obtained from patients treated with Ada, Eta or
Inf. *p<0.05. (C) sTNFRII levels were quantified in the supernatant of PBMCs in the absence or in the
presence of LPS for 24 hours. PBMCs were obtained from patients treated with Ada, Eta or Inf. *p<0.05;
**p<0.01; ***p<0.001.
doi:10.1371/journal.pone.0167757.g004
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Fig 5. Gating strategy used to identify monocyte subsets among PBMCs. Monocytes were first selected on
the basis of their physical parameters, i.e. forward scatter (FSC) and side scatter (SSC). Doublets were eliminated
from the analysis (upper right panel). Then, living monocyes were selected according to the negativity to Live Dead
probe (middle left panel). Cells negative for the DUMP channel (anti-CD3, anti-CD19 and anti-CD56) were then
selected (middle right panel). Among these, monocytes were selected according to positivity to CD14 and HLA-DR
Anti-TNFαDrugs and TNFα-sTNFR System in Patients with Psoriasis
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significant statistical difference among R and NR. However, while the concentration range of
ATIs was 5.4–63.1 ng/ml for R, for NR it was 13.8–422.45 ng/ml, suggesting that a higher con-
centration of ATIs could be involved in therapy ineffectiveness.
Concerning plasma levels of TNF-α, sTNFRI and sTNFRII, the main differences involved
TNF-α levels. Firstly, we found that TNF-α plasma levels do not correlate with the subjects’
age. This was quite unexpected, as in the healthy population TNF-α plasma levels increase
with age [30]. In psoriatic patients, the absence of correlation is probably due to the removal of
TNF-α by the drugs. Conversely, levels of sTNFRI and sTNFRII correlate with patients’ age.
Concerning the different drugs, patients treated with etanercept, both R or NR, display higher
levels of TNF-α compared to patients treated with adalimumab or infliximab. This was unex-
pected, since anti-TNF-α therapy causes a decrease in the frequencies of pro-inflammatory T
helper cells, including Th1 and Th17, and a concomitant decline in their associated cytokines,
principally TNF-α. The more obvious and possible explanation is related to the test that was
used to detect TNF-α in plasma, that could most likely be able to detect both free TNF-α and
TNF-α bound to etanercept. However, whether or not TNF-α was detected by the assay in its
free or bound form, the total concentration of TNF-α in patients treated with etanercept was
higher. Although explorative principal component analysis on immunologic and haematologi-
cal parameters did not reveal any particular cluster of patients, the production of TNF-α and
its soluble receptors was altered when PBMCs were cultured in vitro, in the presence or in the
absence of LPS. When stimulated with LPS, PBMCs from patients responding to etanercept or
adalimumab produce almost 4-fold TNF-α together with sTNFRII than PMBCs from patients
receiving infliximab. PBMCs from patients not responding to infliximab produced higher lev-
els of TNF-α and sTNFRII, whereas PBMCs from patients treated with etanercept and not
responding to this therapy, produced lower levels of sTNFRI. This could partially explain the
higher TNF-α levels observed in these patients’ plasma. Previous studies suggested that etaner-
cept and infliximab strongly affect gene expression in PBMCs, and that effects of etanercept
were different from infliximab in the modulation of proinflammatory genes [31, 32]. Our data
are thus in agreement with above-said observations.
We found that anti-TNF-α drugs also modify monocyte subsets in patients with psoriasis.
Circulating monocytes derive from the bone marrow and mediate both regulatory and effector
functions in adaptive and innate immunity. In response to several stimuli, monocytes can
migrate into tissues where they can differentiate into phagocytes, dendritic cells and osteoclasts
[33]. Three major subsets of circulating monocytes have been identified so far, that differ in
the expression of chemokine receptors, migratory properties, reactive oxygen species genera-
tion, and ability to differentiate into effector cells [34]. The frequency and distribution of
monocyte subsets have been analysed in a variety of inflammatory diseases, including RA, CD
and ulcerative colitis, and in certain cases represent a suitable marker of response to drugs
[35–37]. For instance, the absolute number of monocytes and their subsets has a predictive
value in term of clinical response to adalimumab and methotrexate in RA patients [38]. Inflixi-
mab treatment also induced an increase in intermediate monocytes, which produce high levels
of TNF-α in response to LPS and show phagocytic capacity, thus behaving as proinflammatory
cells [39]. Here we describe variations in the percentages of monocytes and in their subsets in
patients treated with different anti-TNF-α drugs. The percentage of total monocytes, i.e., all
CD14+ cells, as well as the percentage of classical monocytes in patients treated with adalimu-
mab was significantly lower if compared to patients treated with etanercept and infliximab.
(lower left panel). In this population, three monocyte subsets were identified on the basis of the expression of CD14
and CD16 (lower right panel).
doi:10.1371/journal.pone.0167757.g005
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Fig 6. Adalimumab affects the distribution of monocyte subsets. (A) Percentage of CD14+ monocytes (i.e., all
monocytes) in patients treated with adalimumab (Ada), etanercept (Eta) or infliximab (Inf). *p<0.05. (B) Quantification of
HLA-DR expression in CD14+ monocytes. (C) Percentage of CD14++,CD16- (classical) monocytes in patients treated with
Ada, Eta or Inf. *p<0.05. (D) Quantification of HLA-DR expression in CD14++,CD16- monocytes. (E) Percentage of CD14+,
CD16++ (non-classical) monocytes in patients treated with Ada, Eta or Inf. (F) Quantification of HLA-DR expression in CD14
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However, the stratification of patients according to PASI did not reveal any difference in the
percentage of monocyte subsets between R and NR to the different treatments. The loss of
monocytes in patients treated with adalimumab could be caused by three, non-mutually exclu-
sive phenomena, i.e., redistribution and homing of cells, increased differentiation (e.g., towards
osteoclasts), or net loss of cells due to apoptosis. If on the one side, it is difficult to analyze
monocyte redistribution to tissues other than blood, or to detect osteoclastic differentiation,
on the other side, it is possible to hypothesize that, as already demonstrated using in vitro mod-
els [40], these cells are sensitive to a pro-apoptotic action of the drug. Regarding non-classical
monocytes, while their percentage did not vary among different groups, the expression of
HLA-DR was higher in non-classical monocytes from patients treated with infliximab than
non-classical monocytes from patients treated with etanercept. It is well known that the
expression of MHC class II molecules is directly correlated to the capacity to present antigens.
Thus, it is possible to envisage that anti-TNF drugs are also able, to a certain extent, to modu-
late this fundamental function of immune cells.
In summary, our study suggests that a complex remodelling of the TNF-α/sTNFR system
occurs in patients with psoriasis treated with anti-TNF-α drugs. Other studies are, however,
needed to further characterize functional changes of monocytes in patients treated with differ-
ent drugs, and that could devote their attention to other early, crucial aspects of inflammatory
phenomena modulated by these drugs. Therefore, the correlations between plasma levels of
TNF-α, its soluble receptor, the phenotype of monocytes and their ability to produce cytokines
must be investigated also in other human diseases that benefit of he treatment with molecules
that block TNF-α.
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